Inactive Instrument

Press Releases Cocrystal Pharma Inc OTC Bulletin Board

Equities

US19188J1025

Press Releases

Unlock all the news: Be the first to know and act before the market!

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows	06-20	AQ
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	05-13	AQ
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza	05-01	AQ
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	03-28	AQ
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A	03-19	AQ
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates	01-04	AQ
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A	12-06	AQ
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	11-29	AQ
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023	11-27	AQ
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	11-13	AQ
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	11-09	AQ
Cocrystal Pharma : Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 - Form 8-K	23-10-31	PU
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344	23-10-31	AQ
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus	23-09-28	AQ
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference	23-09-05	AQ
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	23-08-14	AQ
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead	23-08-08	AQ
Cocrystal Pharma : Investor Presentation	23-06-24	PU
Cocrystal Pharma : Market Offering Agreement - Form 8-K	23-06-15	PU
Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988	23-05-31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cocrystal Pharma Inc OTC Bulletin Board

Equities

US19188J1025

Press Releases

Filters